Seer (SEER) Q1 2026 Earnings Call Transcript

Seer reported Q1 revenue of $2.8 million, down from $4.2 million a year ago, as lower product and service revenue offset ongoing platform progress. Gross margin fell to 35% from 49%, but operating expenses declined to $18.2 million and the company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million while ending the quarter with $219.5 million in cash and investments. Management highlighted 84 validating publications, a new biobank partnership, a CCO hire, and a patent suit against Nanomix, alongside a $24.5 million share repurchase program that is nearly complete.

Analysis

SEER is in the classic “validation without monetization” phase: scientific credibility is compounding faster than revenue, but the commercial engine is still too small to absorb quarterly volatility. The second-order issue is that patent defense and imitator pressure are no longer just legal noise—they are a pricing and adoption signal, implying the category is valuable enough to attract low-cost copycats, which can temporarily compress margins while also accelerating the need for buyers to choose a standard. That dynamic can actually help the incumbent over 6-18 months if customers conclude that sample integrity and reproducibility matter more than sticker price.

The near-term setup is less about this quarter’s miss and more about the timing of reorder behavior. Management is effectively telling you that instrument placements need 9-12 months to convert into consumable pull-through, which means the installed base from 2025 is the key forward indicator for 2H26. If that lag holds, SEER’s revenue trajectory should inflect before its headline growth rate does, but if utilization fails to lift by late summer, the guidance range becomes vulnerable because there is not enough services scale to offset weakness.

The contrarian read is that the market may be underestimating how much of SEER’s addressable market is being temporarily throttled by funding, not product fit. The public-data events from biobanks and the next-gen detector are the real catalysts; they can move SEER from an academic tool to a workflow standard in translational and biopharma settings, where budgets are more resilient and purchasing cycles are shorter. The risk is that the company keeps winning scientific proof points while competitors keep harvesting price-sensitive demand, leaving SEER with a stronger moat but slower revenue conversion than bulls expect.

Key Decisions for Investors

• Stay tactical long SEER only on weakness into the next biobank/public-data catalyst; use a 3-6 month horizon and size for high volatility, since the stock likely trades on readout timing rather than current-quarter fundamentals.
• Avoid outright chasing the stock until evidence of consumable reorders shows up in 2H26; the cleaner entry is after a confirmed utilization inflection, not after publication headlines.
• Pair trade: long TMO / short SEER for the next 1-2 quarters if you want proteomics exposure without single-name commercialization risk; TMO benefits if SEER’s platform expands the market but has far lower execution and funding sensitivity.
• If long SEER, hedge with a short-dated put spread into the summer data window; downside is meaningful if the installed base does not convert, while upside is capped by the company’s small revenue base and persistent loss profile.
• Do not short aggressively here unless you have evidence the 2025 installed base is stalling; the patent/litigation posture and upcoming data releases create asymmetric squeeze risk if investor sentiment shifts on any credible adoption signal.